ABSTRACT
Background Lean body mass (LBM) composition of cancer patients is a predictor of chemotherapy-related adverse events and overall cancer survival. However, clinicians lack validated algorithms that can be applied to measure the LBM of cancer patients to facilitate accurate chemotherapy dosing. Our goal was to develop LBM predictive equations using routinely measured anthropometric measures among cancer patients.
Methods We leveraged the 1999-2006 National Health and Nutrition Examination Survey (NHANES) data cycles containing information on self-reported cancer diagnosis, LBM measures based on dual-energy x-ray absorptiometry (DXA) and several anthropometric and demographic factors. We restricted our analysis to participants who had been diagnosed with cancer at the time of surveys. The data was randomly split to 75%:25% to train and test predictive models. Least absolute shrinkage and selection operator (LASSO) models were used to predict LBM based on anthropometric and demographic factors, overall and separately among sex and sex-by-race/ethnic subgroups. LBM measured directly with DXA served as the gold standard for assessing the predictive abilities (correlations [R2] and the Root Mean Square Error [RMSE]) of the derived LBM-algorithms. We further compared the correlations between both DXA-based LBM and predicted LBM and urine creatinine levels, a known biomarker of muscle mass.
Results We identified 1,777 cancer patients with a median age of 71 (interquartile range [IQR]: 60-80) years. The most parsimonious model comprised of height and weight, which accurately predicted LBM overall (R2=0.86, RMSE =2.26). The predictive abilities of these models varied across sex-by-race/ethnic groups. The magnitude of correlations between derived LBM-algorithm and urine creatinine levels were larger compared to those measured between DXA-based LBM and urine creatinine levels (R2=0.30 vs. R2=0.17)
Conclusions We successfully developed a simple sex-specific and sex-by-race/ethnicity-specific models to accurately predict the LBM of cancer patients by using only height and weight. The simplicity and high accuracy of these models make them inexpensive alternatives to measuring the LBM of cancer patients. Data on the LBM of cancer patients could help guide optimal chemotherapy dose selection among cancer patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors nor their institutions at any time received payment or services for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because NHANES is a publically available dataset, The Ohio State University IRB did not constitute the project to require human subjects review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure: The authors do not have any disclousures relavent to this study.
Data Availability
All data referred to in the manuscript is publicly available via CDC.
